Jane Street Group LLC Acquires Shares of 134,390 Rockwell Medical, Inc. (NASDAQ:RMTI)

Jane Street Group LLC bought a new stake in Rockwell Medical, Inc. (NASDAQ:RMTI) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 134,390 shares of the company’s stock, valued at approximately $534,000.

A number of other hedge funds have also modified their holdings of the business. Armistice Capital LLC raised its position in shares of Rockwell Medical by 22.5% in the second quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock valued at $5,670,000 after buying an additional 592,000 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of Rockwell Medical in the third quarter valued at about $435,000. Renaissance Technologies LLC raised its position in shares of Rockwell Medical by 877.1% in the second quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock valued at $181,000 after buying an additional 92,189 shares during the last quarter. State Street Corp raised its position in shares of Rockwell Medical by 21.5% in the third quarter. State Street Corp now owns 95,004 shares of the company’s stock valued at $377,000 after buying an additional 16,800 shares during the last quarter. Finally, Corsair Capital Management L.P. acquired a new stake in shares of Rockwell Medical in the third quarter valued at about $298,000. 23.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on RMTI. RODMAN&RENSHAW upgraded shares of Rockwell Medical to a “strong-buy” rating in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Rockwell Medical in a research report on Monday, December 23rd. StockNews.com cut shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Friday, December 20th. Finally, Rodman & Renshaw assumed coverage on shares of Rockwell Medical in a research report on Thursday, November 14th. They set a “buy” rating and a $5.00 price objective for the company.

Rockwell Medical Price Performance

Rockwell Medical stock opened at $2.33 on Monday. Rockwell Medical, Inc. has a 12-month low of $1.16 and a 12-month high of $5.15. The stock has a market cap of $75.30 million, a P/E ratio of -46.60 and a beta of 1.38. The company has a 50-day moving average price of $2.61 and a 200 day moving average price of $2.72. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33.

Rockwell Medical Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.